ANDA 202147, held by Sandoz. Cosyntropin.
As of Nov 15, 2026, ANDA 202147 (Cosyntropin), held by Sandoz, was first approved by FDA on Jun 29, 2012, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Cosyntropin for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (see DOSAGE AND ADMINISTRATION section). Severe hypofunction of the pituitary - adrenal axis is usually associated with subnormal plasma cortisol values but a low basal level is not per se evidence of adrenal insufficiency and does not suffice to make the diagnosis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 29, 2012 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cosyntropin0.25MG/VIAL · injectable;injection | Cosyntropin | Rx |
| Nov 27, 2024 | Supplement 17Labeling · Standard review | Approved | None posted |
| Nov 27, 2024 | Supplement 18Labeling · Standard review | Approved | None posted |
| Jun 29, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters